Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

10x Genomics (TXG) Equity Ratio (2018 - 2025)

10x Genomics (TXG) has disclosed Equity Ratio for 8 consecutive years, with 0.76 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 1.08% to 0.76 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.76 through Dec 2025, down 1.08% year-over-year, with the annual reading at 0.76 for FY2025, 1.08% down from the prior year.
  • Equity Ratio hit 0.76 in Q4 2025 for 10x Genomics, roughly flat from 0.76 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.81 in Q3 2021 to a low of 0.76 in Q3 2025.
  • Historically, Equity Ratio has averaged 0.78 across 5 years, with a median of 0.78 in 2022.
  • Biggest five-year swings in Equity Ratio: rose 19.55% in 2021 and later decreased 3.6% in 2022.
  • Year by year, Equity Ratio stood at 0.8 in 2021, then fell by 2.42% to 0.78 in 2022, then fell by 1.95% to 0.77 in 2023, then grew by 0.68% to 0.77 in 2024, then decreased by 1.08% to 0.76 in 2025.
  • Business Quant data shows Equity Ratio for TXG at 0.76 in Q4 2025, 0.76 in Q3 2025, and 0.79 in Q2 2025.